Important players in the removal of “epigenetic signatures” or post translational modifications on histones are epigenetic erasers.
Epigenetic Erasers from BioVision
These epigenetic reprogramming events are needed during a number of developmental stages. BioVision provides a number of epigenetic erasers and some of them are potential targets for cancer therapeutics.
The balance of histone acetylation and deacetylation plays a key part in transcription regulation. HDAC activity is associated with the gene silencing part of this regulation. Mutation in HDAC structure and alteration in expression has been associated with tumor development, leading to HDACs being a cancer therapeutic target.
About BioVision Incorporated
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.
BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.